Jose Diaz

981 total citations
19 papers, 666 citations indexed

About

Jose Diaz is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Oncology. According to data from OpenAlex, Jose Diaz has authored 19 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Economics and Econometrics and 6 papers in Oncology. Recurrent topics in Jose Diaz's work include Economic and Financial Impacts of Cancer (12 papers), Renal cell carcinoma treatment (10 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Jose Diaz is often cited by papers focused on Economic and Financial Impacts of Cancer (12 papers), Renal cell carcinoma treatment (10 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Jose Diaz collaborates with scholars based in United Kingdom, United States and Canada. Jose Diaz's co-authors include David Cella, Thomas E. Delea, Faisal Mehmud, Robert D. Hawkins, Thomas Powles, Camillo Porta, Sadya Khan, Cora N. Sternberg, Emmanuel Sevin and Suman Redhu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Jose Diaz

17 papers receiving 650 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jose Diaz United Kingdom 12 516 307 230 184 150 19 666
Betsy Higgins United States 11 518 1.0× 123 0.4× 203 0.9× 117 0.6× 11 0.1× 17 742
M Bolla France 9 435 0.8× 81 0.3× 142 0.6× 87 0.5× 20 0.1× 26 765
Boris Duchemann France 19 569 1.1× 149 0.5× 675 2.9× 89 0.5× 8 0.1× 76 1.0k
Amabelle B. Cruz United States 5 582 1.1× 103 0.3× 97 0.4× 131 0.7× 8 0.1× 7 704
Hannah Hazard‐Jenkins United States 13 106 0.2× 117 0.4× 319 1.4× 219 1.2× 30 0.2× 48 569
Noriyoshi Miura Japan 18 343 0.7× 212 0.7× 171 0.7× 119 0.6× 10 0.1× 70 757
Christian Focan Belgium 8 130 0.3× 48 0.2× 323 1.4× 73 0.4× 19 0.1× 10 535
Domen Ribnikar Slovenia 11 151 0.3× 97 0.3× 291 1.3× 199 1.1× 17 0.1× 31 470
Andrea Leith United Kingdom 9 139 0.3× 74 0.2× 64 0.3× 48 0.3× 47 0.3× 24 467
Irene Resch Austria 13 235 0.5× 66 0.2× 178 0.8× 122 0.7× 15 0.1× 33 634

Countries citing papers authored by Jose Diaz

Since Specialization
Citations

This map shows the geographic impact of Jose Diaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jose Diaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jose Diaz more than expected).

Fields of papers citing papers by Jose Diaz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jose Diaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jose Diaz. The network helps show where Jose Diaz may publish in the future.

Co-authorship network of co-authors of Jose Diaz

This figure shows the co-authorship network connecting the top 25 collaborators of Jose Diaz. A scholar is included among the top collaborators of Jose Diaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jose Diaz. Jose Diaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Diaz, Jose, et al.. (2017). Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PLoS ONE. 12(6). e0175920–e0175920. 29 indexed citations
3.
Diaz, Jose, et al.. (2016). Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada. Current Oncology. 23(4). 340–354. 48 indexed citations
4.
Diaz, Jose, et al.. (2016). First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma. Anti-Cancer Drugs. 27(5). 383–397. 19 indexed citations
5.
Diaz, Jose, Cora N. Sternberg, Faisal Mehmud, et al.. (2016). Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology. 90(3). 119–126. 9 indexed citations
6.
Beaumont, Jennifer L., John M. Salsman, Jose Diaz, et al.. (2016). Quality‐adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 122(7). 1108–1115. 28 indexed citations
7.
Martínez‐García, Miguel Ángel, Eusebi Chiner, Luís Hernández, et al.. (2015). Obstructive sleep apnoea in the elderly: role of continuous positive airway pressure treatment. European Respiratory Journal. 46(1). 142–151. 72 indexed citations
8.
Delea, Thomas E., et al.. (2015). Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States. Journal of Managed Care & Specialty Pharmacy. 21(1). 46–54. 36 indexed citations
9.
Lai, Jin‐Shei, Jennifer L. Beaumont, Jose Diaz, Sadya Khan, & David Cella. (2015). Validation of a short questionnaire to measure symptoms and functional limitations associated with hand‐foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer. 122(2). 287–295. 12 indexed citations
10.
Manson, Stephanie, et al.. (2014). Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom. Sarcoma. 2014. 1–14. 14 indexed citations
11.
12.
Beaumont, Jennifer L., Jose Diaz, Keith C. Deen, et al.. (2014). Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN).. Journal of Clinical Oncology. 32(15_suppl). 4581–4581. 2 indexed citations
13.
Escudier, Bernard, Camillo Porta, Petri Bono, et al.. (2014). Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study. Journal of Clinical Oncology. 32(14). 1412–1418. 298 indexed citations
14.
15.
Beaumont, Jennifer L., Jose Diaz, Sadya Khan, & David Cella. (2013). Validation of the supplementary quality of life questionnaire for mouth/throat and hand/foot soreness.. Journal of Clinical Oncology. 31(15_suppl). 9574–9574. 1 indexed citations
16.
Cella, David, Michelle D. Hackshaw, Jose Diaz, et al.. (2013). Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study.. Journal of Clinical Oncology. 31(6_suppl). 346–346. 7 indexed citations
17.
Riemsma, Rob, Carol Forbes, Mayur M. Amonkar, et al.. (2012). Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). Current Medical Research and Opinion. 28(8). 1263–1279. 18 indexed citations
18.
Shingler, S.L., Paul Swinburn, Andrew Lloyd, et al.. (2012). Elicitation of health state utilities in soft tissue sarcoma. Quality of Life Research. 22(7). 1697–1706. 22 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Betsy Higgins Breakdown of academic impact, for papers by M Bolla Breakdown of academic impact, for papers by Boris Duchemann Breakdown of academic impact, for papers by Amabelle B. Cruz Breakdown of academic impact, for papers by Hannah Hazard‐Jenkins Breakdown of academic impact, for papers by Noriyoshi Miura Breakdown of academic impact, for papers by Christian Focan Breakdown of academic impact, for papers by Domen Ribnikar Breakdown of academic impact, for papers by Andrea Leith Breakdown of academic impact, for papers by Irene Resch
Rankless by CCL
2026